{"id":133465,"date":"2026-07-15T08:12:00","date_gmt":"2026-07-15T11:12:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/"},"modified":"2026-07-15T08:12:00","modified_gmt":"2026-07-15T11:12:00","slug":"septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/","title":{"rendered":"Septa Pharmaceuticals Inc. Adquire CeeNU\u00ae (Lomustine) da Bristol Myers Squibb, Canad\u00e1"},"content":{"rendered":"\n
\nMississauga, ON<\/span>, 15 de julho de 2026<\/span> \/PRNewswire\/ — Septa Pharmaceuticals Inc.<\/a>, l\u00edder em r\u00e1pido crescimento no setor de sa\u00fade canadense, tem o orgulho de anunciar a aquisi\u00e7\u00e3o bem-sucedida da CeeNU\u00ae<\/sup><\/a> (Lomustine) da Bristol Myers Squibb, Canad\u00e1 a partir de 29 de junho de 2026. Essa aquisi\u00e7\u00e3o estrat\u00e9gica representa um marco significativo na expans\u00e3o cont\u00ednua da SEPTA e ressalta sua dedica\u00e7\u00e3o inabal\u00e1vel ao fortalecimento de seu portf\u00f3lio farmac\u00eautico especializado em oncologia. CeeNU\u00ae<\/sup><\/a> (Lomustine) \u00e9 um agente alquilante estabelecido e altamente valorizado utilizado principalmente no tratamento de tipos espec\u00edficos de tumores cerebrais e linfoma de Hodgkin. Ao integrar este medicamento quimioter\u00e1pico essencial em sua linha de produtos, a septa est\u00e1 refor\u00e7ando sua presen\u00e7a no espa\u00e7o de cuidados intensivos e oncol\u00f3gicos.<\/p>\n
\"Septa<\/div>\n

CeeNU\u00ae<\/sup><\/a> (Lomustine) representa uma op\u00e7\u00e3o terap\u00eautica importante para muitos indiv\u00edduos que lutam contra condi\u00e7\u00f5es graves de sa\u00fade. Consequentemente, a septa est\u00e1 profundamente empenhada em garantir o acesso cont\u00ednuo e ininterrupto dos pacientes a este medicamento vital em todo o Canad\u00e1. Reconhecendo a necessidade cr\u00edtica de um fornecimento robusto e est\u00e1vel de medicamentos essenciais no complexo cen\u00e1rio de sa\u00fade atual, a septa est\u00e1 priorizando ferozmente a disponibilidade a longo prazo do CeeNU\u00ae<\/sup><\/a> (Lomustine).<\/p>\n

“\u00c0 medida que integramos o CeeNU\u00ae<\/sup><\/a> (Lomustine) em nosso portf\u00f3lio crescente, nosso foco principal permanece firmemente nos pacientes e nos profissionais m\u00e9dicos que os tratam”, disse Devinder K., presidente e CEO da SEPTA Pharmaceuticals Inc.<\/a> “Estamos trabalhando em colabora\u00e7\u00e3o e em estreita colabora\u00e7\u00e3o com todas as partes interessadas relevantes, incluindo \u00f3rg\u00e3os reguladores e parceiros da cadeia de suprimentos, para garantir uma transi\u00e7\u00e3o perfeita. Esta aquisi\u00e7\u00e3o \u00e9 um profundo testemunho de nossa miss\u00e3o principal de fornecer produtos farmac\u00eauticos confi\u00e1veis e de alta qualidade que melhorem de forma tang\u00edvel os resultados de sa\u00fade em todo o pa\u00eds e em todo o mundo.”<\/p>\n

\u00c0 medida que a SEPTA amplia rapidamente seu diversificado portf\u00f3lio de produtos e expande territ\u00f3rios geogr\u00e1ficos, a empresa est\u00e1 buscando ativamente novas parcerias estrat\u00e9gicas e oportunidades de licenciamento. Congratulamo-nos com colabora\u00e7\u00f5es com empresas farmac\u00eauticas para out\/in-license, lan\u00e7amento e comercializa\u00e7\u00e3o de tais terapias de alto impacto a n\u00edvel mundial. Juntos, podemos impulsionar o crescimento m\u00fatuo e garantir que medicamentos vitais cheguem aos mercados globais.<\/p>\n

Sobre a Septa Pharmaceuticals Inc.<\/b><\/p>\n

Com sede em Ont\u00e1rio, Canad\u00e1, a SEPTA Pharmaceuticals Inc.<\/a> \u00e9 uma empresa farmac\u00eautica com vis\u00e3o de futuro dedicada ao desenvolvimento, aquisi\u00e7\u00e3o e comercializa\u00e7\u00e3o de produtos farmac\u00eauticos especializados em todo o mundo. Com uma filosofia voltada para o paciente, a septa se esfor\u00e7a consistentemente para preencher as lacunas no mercado de sa\u00fade, garantindo e estabilizando o fornecimento de medicamentos essenciais. Por meio de parcerias estrat\u00e9gicas e aquisi\u00e7\u00f5es direcionadas, a SEPTA continua a construir um pipeline de produtos robusto e programas de acesso gerenciado projetados para atender \u00e0s necessidades crescentes da comunidade m\u00e9dica global.<\/p>\n

Logo – https:\/\/mma.prnewswire.com\/media\/3005802\/Septa_Pharmaceuticals_Inc__Septa_Pharmaceuticals_Inc__Acquires_C.jpg<\/a><\/p>\n

\"Cision\" View original content:https:\/\/www.prnewswire.com\/br\/comunicados-para-a-imprensa\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada-302824583.html<\/a><\/p>\n

FONTE Septa Pharmaceuticals Inc.<\/p>\n<\/div>\n

\"\"<\/p>\n

T\u00f3picos Relacionados:<\/strong> M\u00e9dico \/ Farmac\u00eautico, Produtos Farmac\u00eauticos, Aquisi\u00e7\u00f5es, Fus\u00f5es, Incorpora\u00e7\u00f5es, Sa\u00fade\/Hospitais<\/p>\n

A OESP<\/b> n\u00e3o \u00e9(s\u00e3o) respons\u00e1vel(is) por erros, incorre\u00e7\u00f5es, atrasos ou quaisquer decis\u00f5es tomadas por seus clientes com base nos Conte\u00fados ora disponibilizados, bem como tais Conte\u00fados n\u00e3o representam a opini\u00e3o da OESP<\/b> e s\u00e3o de inteira responsabilidade da PR Newswire Ltda<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"Mississauga, ON, 15 de julho de 2026 \/PRNewswire\/ — Septa Pharmaceuticals Inc., l\u00edder em r\u00e1pido crescimento no setor de sa\u00fade canadense, tem o orgulho de anunciar a aquisi\u00e7\u00e3o bem-sucedida","protected":false},"author":1,"featured_media":133466,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[27],"tags":[11539,11538,11540],"class_list":["post-133465","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-prnewswire","tag-lider-em-rapido-crescimento-no-setor-de-saude-canadense","tag-septa-pharmaceuticals-inc","tag-tem-o-orgulho-de-anunciar-a-aquisicao-bem-sucedida-da-ceenu-lomustine-da-bristol-myers-squi"],"acf":[],"yoast_head":"\nSepta Pharmaceuticals Inc. Adquire CeeNU\u00ae (Lomustine) da Bristol Myers Squibb, Canad\u00e1 - Ag\u00eancia de Comunica\u00e7\u00e3o<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Septa Pharmaceuticals Inc. Adquire CeeNU\u00ae (Lomustine) da Bristol Myers Squibb, Canad\u00e1 - Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"og:description\" content=\"Mississauga, ON, 15 de julho de 2026 \/PRNewswire\/ — Septa Pharmaceuticals Inc., l\u00edder em r\u00e1pido crescimento no setor de sa\u00fade canadense, tem o orgulho de anunciar a aquisi\u00e7\u00e3o bem-sucedida\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/\" \/>\n<meta property=\"og:site_name\" content=\"Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T11:12:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2026\/07\/1_53_2_2026-07-15_11.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"patric_oliveira\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"patric_oliveira\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\\\/\"},\"author\":{\"name\":\"patric_oliveira\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"headline\":\"Septa Pharmaceuticals Inc. Adquire CeeNU\u00ae (Lomustine) da Bristol Myers Squibb, Canad\u00e1\",\"datePublished\":\"2026-07-15T11:12:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\\\/\"},\"wordCount\":618,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1_53_2_2026-07-15_11.jpg\",\"keywords\":[\"l\u00edder em r\u00e1pido crescimento no setor de sa\u00fade canadense\",\"Septa Pharmaceuticals Inc.\",\"tem o orgulho de anunciar a aquisi\u00e7\u00e3o bem-sucedida da CeeNU\u00ae (Lomustine) da Bristol Myers Squi\"],\"articleSection\":[\"PR Newswire\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\\\/\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\\\/\",\"name\":\"Septa Pharmaceuticals Inc. Adquire CeeNU\u00ae (Lomustine) da Bristol Myers Squibb, Canad\u00e1 - Ag\u00eancia de Comunica\u00e7\u00e3o\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1_53_2_2026-07-15_11.jpg\",\"datePublished\":\"2026-07-15T11:12:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\\\/#primaryimage\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1_53_2_2026-07-15_11.jpg\",\"contentUrl\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1_53_2_2026-07-15_11.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Septa Pharmaceuticals Inc. Adquire CeeNU\u00ae (Lomustine) da Bristol Myers Squibb, Canad\u00e1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\",\"name\":\"Ag\u00eancia de Comunica\u00e7\u00e3o\",\"description\":\"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\",\"name\":\"patric_oliveira\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"caption\":\"patric_oliveira\"},\"sameAs\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"],\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/author\\\/patric_oliveira\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Septa Pharmaceuticals Inc. Adquire CeeNU\u00ae (Lomustine) da Bristol Myers Squibb, Canad\u00e1 - Ag\u00eancia de Comunica\u00e7\u00e3o","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/","og_locale":"pt_BR","og_type":"article","og_title":"Septa Pharmaceuticals Inc. Adquire CeeNU\u00ae (Lomustine) da Bristol Myers Squibb, Canad\u00e1 - Ag\u00eancia de Comunica\u00e7\u00e3o","og_description":"Mississauga, ON, 15 de julho de 2026 \/PRNewswire\/ — Septa Pharmaceuticals Inc., l\u00edder em r\u00e1pido crescimento no setor de sa\u00fade canadense, tem o orgulho de anunciar a aquisi\u00e7\u00e3o bem-sucedida","og_url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/","og_site_name":"Ag\u00eancia de Comunica\u00e7\u00e3o","article_published_time":"2026-07-15T11:12:00+00:00","og_image":[{"url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2026\/07\/1_53_2_2026-07-15_11.jpg","width":1,"height":1,"type":"image\/jpeg"}],"author":"patric_oliveira","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"patric_oliveira","Est. tempo de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/#article","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/"},"author":{"name":"patric_oliveira","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"headline":"Septa Pharmaceuticals Inc. Adquire CeeNU\u00ae (Lomustine) da Bristol Myers Squibb, Canad\u00e1","datePublished":"2026-07-15T11:12:00+00:00","mainEntityOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/"},"wordCount":618,"commentCount":0,"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2026\/07\/1_53_2_2026-07-15_11.jpg","keywords":["l\u00edder em r\u00e1pido crescimento no setor de sa\u00fade canadense","Septa Pharmaceuticals Inc.","tem o orgulho de anunciar a aquisi\u00e7\u00e3o bem-sucedida da CeeNU\u00ae (Lomustine) da Bristol Myers Squi"],"articleSection":["PR Newswire"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/","name":"Septa Pharmaceuticals Inc. Adquire CeeNU\u00ae (Lomustine) da Bristol Myers Squibb, Canad\u00e1 - Ag\u00eancia de Comunica\u00e7\u00e3o","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/#primaryimage"},"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2026\/07\/1_53_2_2026-07-15_11.jpg","datePublished":"2026-07-15T11:12:00+00:00","author":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"breadcrumb":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/#primaryimage","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2026\/07\/1_53_2_2026-07-15_11.jpg","contentUrl":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2026\/07\/1_53_2_2026-07-15_11.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/septa-pharmaceuticals-inc-adquire-ceenu-lomustine-da-bristol-myers-squibb-canada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"},{"@type":"ListItem","position":2,"name":"Septa Pharmaceuticals Inc. Adquire CeeNU\u00ae (Lomustine) da Bristol Myers Squibb, Canad\u00e1"}]},{"@type":"WebSite","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/","name":"Ag\u00eancia de Comunica\u00e7\u00e3o","description":"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37","name":"patric_oliveira","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","caption":"patric_oliveira"},"sameAs":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"],"url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/author\/patric_oliveira\/"}]}},"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/133465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=133465"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/133465\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media\/133466"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=133465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=133465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=133465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}